Generex Biotechnology Corporation
GNBTQ
OTC PK
| 04/30/2021 | 01/31/2021 | 10/31/2020 | 07/31/2020 | 04/30/2020 | |
|---|---|---|---|---|---|
| Net Income | 138.30% | -124.41% | 8.07% | -107.47% | 18.57% |
| Total Depreciation and Amortization | -0.57% | 1.33% | -13.79% | 41.15% | -0.61% |
| Total Amortization of Deferred Charges | 282.43% | -4.48% | -71.93% | -26.21% | -5.59% |
| Total Other Non-Cash Items | -204.29% | 633.10% | -147.90% | 427.24% | -28.43% |
| Change in Net Operating Assets | -6.26% | -40.12% | 196.00% | 58.32% | 80.84% |
| Cash from Operations | 158.83% | 26.60% | -110.58% | 27.26% | 68.59% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -75.97% | -57.44% |
| Total Debt Repaid | -3,214.81% | -12.50% | -- | -- | -- |
| Issuance of Common Stock | -29.30% | -55.85% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.83% | -- | -- | -- | -- |
| Cash from Financing | -32.16% | -65.66% | 779.96% | -75.97% | -59.30% |
| Foreign Exchange rate Adjustments | -- | 200.00% | 81.51% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 554.32% | -129.03% | 303.91% | -371.82% | 154.42% |
